NL-OMON51975已完成2 期
Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in obese humans - Obese human beta-2 adrenergic stimulation and muscle glucose uptake
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Male or (postmenopausal; defined as 1 year after the last cycle) female;
- •2. Age between 40-75 years;
- •3. BMI: 25-35 kg/m2;
排除标准
- •1. Not meeting all inclusion criteria
- •2. Cardiovascular disease (determined by means of questionnaires, heart
- •rate/blood pressure measurements and an ECG)
- •3. Respiratory diseases (including asthma, bronchitis and COPD);
- •4. Unstable body weight (weight gain or loss > 5 kg in the last three months);
- •5. Intention to lose or gain body weight (e.g. with caloric restriction or
- •physical activity)
- •6. Excessive alcohol and/or drug abuse;
- •7. Hypokalaemia;
- •8. Hyperthyroidism
- •9. Anaemia;
- •10. Epilepsy;
- •11. Smoking;
- •12. Renal and/or liver insufficiency;
- •13. Diagnosed with type 1 or type 2 diabetes mellitus;
- •14. Any contra-indications to MRI scanning. These contra-indications include
- •patients with:
- •a. Electronic implants such as pacemakers, defibrillators or neurostimulators
- •b. Central nervous system aneurysm clip
- •c. Some hearing aids (such as cochlear implant) and artificial (heart) valves
- •which are contraindicated for MRI/MRS
- •d. Iron containing corpora aliena in the eye or brains
- •e. Claustrophobia
- •15. Participation in another biomedical study within 1 month before the first
- •study visit, possibly interfering with the study results;
- •16. Medication use known to hamper subject*s safety during the study
- •procedures; *
- •17. Subjects who do not want to be informed about unexpected medical findings; *
- •18. Subjects who do not want that their treating physician to be informed;
- •19. Inability to participate and/or complete the required measurements;
- •20. Participation in organised or structured physical exercise;
- •21. Any condition, disease or abnormal laboratory test result that, in the
- •opinion of the Investigator, would interfere with the study outcome, affect
- •trial participation or put the subject at undue risk;
研究者
相似试验
进行中（未招募）
1 期
Investigation of a new way for sugar uptake by the skeletal muscle in obese humansEUCTR2021-000731-31-NLMaastricht University40
进行中（未招募）
1 期
Investigation of a new way for sugar uptake by the skeletal muscle.EUCTR2018-004245-16-NLMaastricht University16
已完成
2 期
Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in healthy humanstype 2 diabetes10018424diabetesNL-OMON50072niversiteit Maastricht23
进行中（未招募）
1 期
Activation of human brown adipose tissue with the use of salbutamolObesity, overweight, lipid- and glucose metabolismMedDRA version: 20.0Level: LLTClassification code 10029885Term: Obesity, unspecifiedSystem Organ Class: 100000004861EUCTR2020-004059-34-NLeiden University Medical Center10
已完成
不适用
The beta-2 adrenergic receptor in human BATNL-OMON27924A10